Short answer
Danaher Corporation (DHR) filed an 8-K current report with the SEC on October 21, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Danaher announced financial results for the quarter ended September 25, 2026.
Danaher Corporation 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Danaher announced financial results for the quarter ended September 25, 2026
- Earnings details and management commentary available in Exhibit 99.1
- Quarterly results provide updated visibility into operating performance and financial condition
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $6.6B, up 8.5%, with core growth excluding respiratory testing accelerating to 5.5%
- Net earnings $1.2B, or $1.71 diluted EPS, up 34.5%; adjusted EPS $2.11, up 11.5%
- Diagnostics GAAP sales grew 17.0%, but acquisitions and divestitures reduced reported growth by 16.5 percentage points
- Operating cash flow $1.9B and free cash flow $1.6B, up approximately 13.5% and 19.0% year-over-year
- Full-year adjusted EPS guidance raised to $8.57-$8.62; Q4 respiratory revenue expected as approximately 150-basis-point headwind
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Danaher Corporation 8-K filings
Get the next DHR 8-K as it lands
Follow DHR for push alerts, or ask the research agent what this filing means.